Letrozole Tablet, Film Coated
Product Images NDC 68071-2167

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 68071-2167). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2167 4)

Label for Letrozole 2.5 mg film-coated tablets from NuCare Pharmaceuticals, Inc. The label indicates a quantity of 40 tablets. It describes the tablets as round, biconvex, yellow, imprinted with 'LT' on one side, plain on the other. The label includes NDC 68071-2167 and mentions manufacturing by Intas Pharmaceuticals Limited, India. Storage instructions state controlled temperature of 68-77°F, with a warning to keep out of reach of children.*

FDA Label Image

Figure 1 Disease-free Survival (median Follow-up 73 Months, Itt Approach) (Letrozole Fig1)

A Kaplan-Meier survival curve comparing treatment outcomes for Letrozole and Tamoxifen over 72 months. The graph shows the proportion of patients remaining event-free, with separate lines representing Letrozole and Tamoxifen. Patient numbers at risk are listed below the x-axis at various time points.*

FDA Label Image

Figure 2 Kaplan-meier Estimates Of Time To Progression (tamoxifen Study) (Letrozole Fig2)

A line graph comparing progression-free survival over months between Letrozole 2.5 mg tablets and Tamoxifen 20 mg. The x-axis represents time in months up to 60, and the y-axis shows progression-free proportion from 0 to 1. Two curves illustrate the progression-free rates for each treatment over time.*

FDA Label Image

Figure 3 Survival By Randomized Treatment Arm (Letrozole Fig3)

A Kaplan-Meier survival curve comparing the probability of being alive over time (in months) between patients receiving letrozole and tamoxifen as first-line treatments. The x-axis represents months up to 60, and the y-axis shows survival probability from 0 to 1. Two survival curves are shown: one solid line for letrozole and one dashed line for tamoxifen.*

FDA Label Image

Figure 4 Kaplan-meier Estimates Of Time To Progression (megestrol Acetate Study) (Letrozole Fig4)

A Kaplan-Meier curve displaying time to progression in days for three treatment groups: Letrozole 0.5 mg tablets, Letrozole 2.5 mg tablets, and a comparison group labeled MA. The y-axis represents the probability of progression over time up to approximately 1000 days.*

FDA Label Image

Figure 5 Kaplan-meier Estimates Of Time To Progression (aminoglutethimide Study) (Letrozole Fig5)

A Kaplan-Meier survival curve chart comparing time to progression (in days) for three treatment groups involving Letrozole tablets at 0.5 mg and 2.5 mg doses, and a third group labeled AG. The chart shows survival probabilities over approximately 900 days.*

FDA Label Image

Letrozole Structural Formula (Letrozole Str)

Chemical structure diagram of letrozole showing its molecular framework with two cyanophenyl groups and a triazole ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.